With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 30 2017. The standard adjuvant therapy for stage III colon cancer has been put to the test with prelim data reported in JCO. A pre-planned pooled non-inferiority analysis of six randomized trials compared the standard 6 months with only 3 months of adjuvant oxaliplatin as part of combo chemo. The primary endpoint of disease-free survival (DFS) at 3 years for the combined 12,834 patients was 75.5% (6 months) versus 74.6% (3 months)--which did not meet pre-specified non-inferiority thresholds (we were surprised, too). Unsurprisingly, several subset analyses did show non-inferiority of the shorter regimen. Notably, 6 months had over triple the rates of neuropathy than 3 months. So with these utterly similar DFS outcomes, colon cancer patients may reasonably choose to opt out of double the adjuvant chemo...and tingly toes.